Study Design for Retrospective Evaluation of MACE in Lung Cancer Patients Receiving ICI
Retrospective study of MACE in lung cancer patients receiving ICIs. Patients receiving ICIs for lung cancer were retrospectively identified (n = 196) for MACE. Patients without MACE included those without any irAEs (n = 20), other noncardiac irAEs (n = 58), or disease progression (n = 95). ICI = immune checkpoint inhibitors; irAEs = immune-related adverse events (irAEs); MACE = major adverse cardiac events.